Recent Security Class Actions

Intellia Therapeutics Inc. Common Stock (NASDAQ: NTLA)

Company Name:Intellia Therapeutics Inc. Common Stock
Stock Symbol:NASDAQ: NTLA
Class Period Start:07/30/2024
Class Period End (inclusive):01/08/2025
Filing Deadline:04/14/2025

According to the complaint, defendants provided investors with material information concerning Intellia's Phase 1/2 study evaluating NTLA-3001 for the treatment of alpha-1 antitrypsin deficiency (AATD)-associated lung disease. Defendants’ statements included, among other things, confidence in the Company’s timeline for the aforementioned study, specifically that Intellia expected to dose the first patient in the second half of 2024. Defendants failed to disclose inter alia that the demand for viral-based editing was rapidly dwindling as non-viral delivery methods became a main target of the scientific research community due to their cost-effectiveness and more efficient development, thus making NTLA-3001 an inefficient program for Intellia to maintain.